MAMunir A. Al-Zeer

Munir A. Al-Zeer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Munir A. Al-Zeer has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas F. Meyer

    Laboratory of Infection Oncology, Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel and University Hospital Schleswig-Holstein, Kiel, Germany

    3 shared publications
  • Mohammad Abu Lubad

    Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany; Mu'tah University, Faculty of Medicine, Al-Karak, Jordan

    2 shared publications
  • Audrey Xavier

    Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany; The Max Delbrück Center for Molecular Medicine, Berlin, Germany

    1 shared publication
  • Daniel Lauster

    Institute of Pharmacy, Biopharmaceuticals, Freie Universität Berlin, Berlin, Germany

    1 shared publication
  • Hesham M. Al-Younes

    Department of Biological Sciences; Faculty of Science; University of Jordan; Amman, Jordan

    1 shared publication
  • Janine Sigulla

    Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany

    1 shared publication

Latest Publications

  • Open Access

    Chlamydia trachomatis Prevents Apoptosis Via Activation of PDPK1-MYC and Enhanced Mitochondrial Binding of Hexokinase II

    by Munir A. Al-Zeer, Audrey Xavier, Mohammad Abu Lubad, Janine Sigulla, Mirjana Kessler, Robert Hurwitz, Thomas F. Meyer


  • Chlamydia trachomatis Inhibits Inducible NO Synthase in Human Mesenchymal Stem Cells by Stimulating Polyamine Synthesis

    by Mohammad Abu-Lubad, Thomas F Meyer, Munir A Al-Zeer

    Chlamydia trachomatis is considered the most common agent of sexually transmitted disease worldwide. As an obligate intracellular bacterium, it relies on the host for survival. Production of NO is an effective antimicrobial defense mechanism of the innate immune system. However, whether NO is able to arrest chlamydial growth remains unclear. Similarly, little is known about the mechanisms underlying subversion of cellular innate immunity by C. trachomatis. By analyzing protein and mRNA expression in infected human mesenchymal stem cells, combined with RNA interference and biochemical assays, we observed that infection with C. trachomatis led to downregulated expression of inducible NO synthase (iNOS) in human mesenchymal stem cells in vitro. Furthermore, infection upregulated the expression of the rate-limiting enzyme in the polyamine biosynthetic pathway, ornithine decarboxylase, diverting the iNOS substrate l-arginine toward the synthesis of polyamines. Inhibition of ornithine decarboxylase activity using small interfering RNA or the competitive inhibitor difluoromethylornithine restored iNOS protein expression and activity in infected cells and inhibited chlamydial growth. This inhibition was mediated through tyrosine nitration of chlamydial protein by peroxynitrite, an NO metabolite. Thus, Chlamydia evades innate immunity by inhibiting NO production through induction of the alternative polyamine pathway.


  • Open Access

    Autophagy restrictsChlamydia trachomatisgrowth in human macrophages via IFNG-inducible guanylate binding proteins

    by Munir A. Al-Zeer, Hesham M. Al-Younes, Daniel Lauster, Mohammad Abu Lubad, Thomas F. Meyer

    Interferon γ (IFNG) is a key host response regulator of intracellular pathogen replication, including that of Chlamydia spp The antichlamydial functions of IFNG manifest in a strictly host, cell-type and chlamydial strain dependent manner. It has been recently shown that the IFNG-inducible family of immunity-related GTPases (IRG) proteins plays a key role in the defense against nonhost adapted chlamydia strains in murine epithelial cells. In humans, IFN-inducible guanylate binding proteins (hGBPs) have been shown to potentiate the antichlamydial effect of IFNG; however, how hGBPs regulate this property of IFNG is unknown. In this study, we identified hGBP1/2 as important resistance factors against C. trachomatis infection in IFNG-stimulated human macrophages. Exogenous IFNG reduced chlamydial infectivity by 50 percent in wild-type cells, whereas shRNA hGBP1/2 knockdown macrophages fully supported chlamydial growth in the presence of exogenous IFNG. hGBP1/2 were recruited to bacterial inclusions in human macrophages upon stimulation with IFNG, which triggered rerouting of the typically nonfusogenic bacterial inclusions for lysosomal degradation. Inhibition of lysosomal activity and autophagy impaired the IFNG-mediated elimination of inclusions. Thus, hGBP1/2 are critical effectors of antichlamydial IFNG responses in human macrophages. Through their capacity to remodel classically nonfusogenic chlamydial inclusions and stimulate fusion with autophagosomes, hGBP1/2 disable a major chlamydial virulence mechanism and contribute to IFNG-mediated pathogen clearance.